Neoadjuvant immune-checkpoint inhibitors in lung cancer - a primer for radiologists.
Immune-checkpoint inhibitor therapy
Immunotherapy
Lung cancer
NSCLC
Neoadjuvant
PET-CT
Response
Journal
European journal of radiology
ISSN: 1872-7727
Titre abrégé: Eur J Radiol
Pays: Ireland
ID NLM: 8106411
Informations de publication
Date de publication:
Apr 2023
Apr 2023
Historique:
received:
01
02
2023
accepted:
03
02
2023
pubmed:
23
2
2023
medline:
21
3
2023
entrez:
22
2
2023
Statut:
ppublish
Résumé
The introduction of neoadjuvant immune checkpoint inhibitors plus platinum-based chemotherapy has changed treatment regimens of patient's early-stage lung cancer. This treatment combination induces high rates of complete pathologic response and improves clinical endpoints. Imaging plays a fundamental role in assessment of treatment response, monitoring of (immune-related) adverse events and enables both the surgeon and pathologist optimal treatment and diagnostic workup of the resected tumor samples. Knowledge of the strengths and weaknesses of diagnostic imaging in this setting are essential for radiologists to provide valuable input in multidisciplinary team decisions.
Identifiants
pubmed: 36804313
pii: S0720-048X(23)00046-3
doi: 10.1016/j.ejrad.2023.110732
pii:
doi:
Substances chimiques
Immune Checkpoint Inhibitors
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
110732Informations de copyright
Copyright © 2023 The Authors. Published by Elsevier B.V. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper: [Helmut Prosch reports financial support was provided by Christian Doppler Laboratories. Lucian Beer reports a relationship with Bayer, Novartis, MSD, Roche that includes: speaking and lecture fees and travel reimbursement].